Genetic medicine: the next generation
A new report from Evaluate Vantage looks at new approaches aiming to solve problems facing the current generation of genetic medicines.
The year the regulators meet the microbiome
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
A radical strategy for Medtronic
The sellside expects the world’s leading medtech to be outpaced by its rivals. Divestments might allow the group to defy this destiny.
Atea’s woes grow while other Covid readouts approach
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.
A remyelinating agent remains a distant hope
But the pipeline contains various approaches that are worth watching, with data from Abbvie possibly the next big event.
The heat is on for Oxford Nanopore
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
The lung fibrosis pipeline thins
This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
Biogen leads the amyotrophic lateral sclerosis hopefuls
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
